Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now

PLoS Medicine

Volumn 13, Issue 9, 2016, Pages

  Mofenson, Lynne M ^a  

^a ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; TENOFOVIR;

ARTICLE; BREAST FEEDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; NONHUMAN; OUTCOME ASSESSMENT; PREGNANCY; PROPHYLAXIS; RESEARCH; WORLD HEALTH ORGANIZATION;

EID: 84989830575     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002133     Document Type: Article

References (29)

1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV pre-exposure prophylaxis for all populations. AIDS. 2016Jul31;30(12):1973–83. doi: 10.1097/QAD.000000000000114527149090
2. World Health OrganizationConsolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection—recommendations for a public health approach—second edition, 2016. Geneva, Switzerland: World Health Organization, 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/.
3. Drake AL, Wagner A, Richardson B, John-Stewart G, Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001608. doi: 10.1371/journal.pmed.100160824586123
4. VIREAD drug label, revised 02/2016. Gilead, Foster City, CA, 2016. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/viread/viread_pi.pdf.
5. Mugwanya KK, Hendrix CW, Mugo NR, Marzinke M, Katabira ET, Ngure K, et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med. 2016; 11:e1002133. doi: 10.1371/journal.pmed.1002133
6. Corbett AH, Kayira D, White NR, Davis NL, Kourtis AP, Chasela C, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study. Antivir Ther. 2014;19:587–95. doi: 10.3851/IMP273924464632
7. Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C, et al. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antivir Ther. 2013;18:585–90. doi: 10.3851/IMP247423183881
8. Palombi L, Pirillo MF, Marchei E, Jere H, Sagno JB, Luhanga R, et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under Option B-Plus approach in Malawi. J Antimicrob Chemother. 2016;71:1027–30. doi: 10.1093/jac/dkv43526679247
9. Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother. 2011Mar;55(3):1315–7. doi: 10.1128/AAC.00514-1021173182
10. Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, HPTN 057 Protocol Teamet al; Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014Jan1;65(1):33–41. doi: 10.1097/QAI.0b013e3182a921eb23979002
11. Noguchi LM, Montgomery ET, Biggio GR, Hendrix CW, Bogen DL, Hillier SL, et al. Topical tenofovir pharmacokinetics in breastfeeding mother-infant pairs. Antimicrob Agents Chemother. 2016July11. pii: AAC.00645-16. [Epub ahead of print].
12. Harrison A, Colvin CJ, Kuo C, Swartz A, Lurie M, Sustained high HIV incidence in young women in southern Africa: social, behavioral and structural factors and emerging intervention approaches. Curr HIV/AIDS Rpt. 2015;12:207–15.
13. UNAIDS. How AIDS changed everything; MDG 6: 15 years, 15 lessons of hope from the AIDS response. UNAIDS, Geneva, Switzerland, 2015. http://www.unaids.org/en/resources/documents/2015/MDG6_15years-15lessonsfromtheAIDSresponse.
14. United Nations Population Fund (UNFPA). Adolescent pregnancy: a review of the evidence. UNFPA, New York, NY. 2013. http://www.unfpa.org/sites/default/files/pub-pdf/ADOLESCENT%20PREGNANCY_UNFPA.pdf.
15. De Schacht C, Mabunda N, Ferreira OC, Ismael N, Calú N, Santos I, et al. High HIV incidence in the postpartum period sustains vertical transmission in settings with generalized epidemics: a cohort study in Southern Mozambique. J Int AIDS Soc. 2014;17:18808. doi: 10.7448/IAS.17.1.1880824629842
16. Humphrey JH, Marinda E, Mutasa K, Moulton LH, Iliff PJ, Ntozini R, et al. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study. BMJ. 2010;341:c6580. doi: 10.1136/bmj.c658021177735
17. Moodley D, Esterhuizen T, Reddy L, Moodley P, Singh B, Ngaleka L, et al. Incident HIV infection in pregnant and lactating women and its effect on mother-to-child transmission in South Africa. J Infect Dis. 2011;203:1231–4. doi: 10.1093/infdis/jir01721398393
18. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M, Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013Dec;57(12):1773–81. doi: 10.1093/cid/cit60124046310
19. Heffron R, Pintyre J, Matthews LT, Weber S, Mugo N, PrEP as peri-conception HIV prevention for women and men. Curr HIV/AIDS Rep. 2016;13:131–9. doi: 10.1007/s11904-016-0312-126993627
20. Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S, et al. Reassuring birth outcomes with tenofovir/emtricitabine/efavirenz used for prevention of mother-to-child transmission of HIV in Botswana. J Acquir Immune Defic Syndr. 2016;71:428–36. doi: 10.1097/QAI.000000000000084726379069
21. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206:1695–705. doi: 10.1093/infdis/jis55323066160
22. Zou H, Chen Y, Duan Z, Zhang H, Pan C, Virologic factors associated with failure of passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19:e18–25. doi: 10.1111/j.1365-2893.2011.01492.x22239517
23. Brown RS, JrMcMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63:319–33. doi: 10.1002/hep.2830226565396
24. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374:2324–34. doi: 10.1056/NEJMoa150866027305192
25. Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Partners PrEP Study Teamet al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312:362–71. doi: 10.1001/jama.2014.873525038355
26. Bunge K, Balkus J, Noguchi L, Pan J, Piper J, Kabwigu S, et al. Pregnancy incidence and outcomes in women receiving tenofovir-based PrEP in the VOICE trial. International AIDS Conference. July 2015, Vancouver, Canada. Abs. MOPEC480.
27. Marrazzo JM, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18. doi: 10.1056/NEJMoa140226925651245
28. Price JT, Wheeler SB, Stranix-Chibanda L, Hosek SG, Watts DH, Siberry GK, et al. Cost-effectiveness of pre-exposure prophylaxis during pregnancy and breastfeeding in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2016;72 (Suppl 2);S145–53. doi: 10.1097/QAI.000000000000106327355502
29. Mujugira A, Celum C, Coombs RW, Campbell JD, Ndase P, Ronald A, Partners PrEP Study Teamet al; HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2016Aug15;72(5):579–84. doi: 10.1097/QAI.000000000000101927070123